Biogen 3Q Revenues: $3.4 billion (-6%) 3Q Earnings: $702 million (-55%) YTD Revenues: $10.6 billion (-1%) YTD Earnings: $3.6 billion (-18%) Commetns: Multiple sclerosis revenues, including $272 million in royalties on sales of OCREVUS, decreased 4%. Total Interferon sales (AVONEX and PLEGRIDY) were down 11% to $474 million. TYSABRI sales were $516 million up 7%. SPINRAZA revenues decreased 10% to $495 million. Biosimilars revenues increased 13% versus the prior year to $208 ...